Prolonged use of contact lenses, trauma, surgery, viral infections, pinkeye, and trachoma cause the cornea to produce new blood vessels, leading to loss of corneal transparency and scarring, and eventually resulting in reduced vision or even blindness in advanced cases. Furthermore, corneal neovascularization is the leading cause of corneal transplant failure (30%).

As a novel targeted genetically engineered drug, KH906 will fill the gap in the market for the treatment of ocular neovascularization.

*This is in clinical trials